PAHC PHIBRO ANIMAL HEALTH CORP

NEUTRAL Impact: 4/10 8-K
Horizon weeks Filed Apr 30, 2026 Processed 1mo ago SEC 0001104659-26-052956
8-K material event: Items 1.01
Latest settled — T+20d
PAHC ▼ -45.58% at T+20d
NEUTRAL call ✗ call lost -45.58% · α vs SPY -50.85% · entry $54.66 → $29.74
Next anchor: T+60d in 6w
Currently $31.53 · -42.32% from $54.66 entry
Entry anchored
Apr 30, 2026
via day open
T+1d
-0.38%
call -0.38% · α -0.04%
$54.45
settled 6w ago
T+5d
-27.13%
call -27.13% · α -29.47%
$39.83
settled 5w ago
T+20d
-45.58%
call -45.58% · α -50.85%
$29.74
settled 15d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Phibro Animal Health Corp. entered into Amendment No. 1 to its existing Credit Agreement, increasing its revolving credit commitment by $125 million from $310 million to $435 million. The amendment was executed with Coöperatieve Rabobank U.A., New York Branch, as administrative agent, and multiple incremental revolving lenders. This is a routine liquidity enhancement that increases the company's financial flexibility without any indication of distress or material change in operations.

Key Financial Metrics

Deal Value
$125.0M

Actionable Insight

The increased revolver provides PAHC with additional liquidity headroom for general corporate purposes, including working capital and potential acquisitions. Monitor upcoming quarterly filings for any deployment of this capacity and for any changes in leverage ratios.

Key Facts

  • Revolving credit commitment increased by $125,000,000 from $310,000,000 to $435,000,000
  • Amendment No. 1 dated April 28, 2026
  • Incremental revolving lenders include Rabobank, Bank of America, Compeer Financial, Citibank, Farm Credit East, City National Bank, BMO Bank, and others
  • Upfront fee of 0.15% paid to each incremental revolving lender
  • No Default or Event of Default existed at effectiveness
  • Pro Forma Compliance with financial covenants was satisfied
  • Existing guarantees and security interests were reaffirmed

Financial Impact

Revolving credit facility increased by $125,000,000 to $435,000,000 total

liquiditydebt capacity

Risk Factors

  • Increased debt capacity could lead to higher leverage if fully drawn
  • No material change in business fundamentals from this filing alone

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
11% bullish (9 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-052956
Document: tm2613052d1_8k.htm0001104659-26-052956
Document: 0001104659-26-052956-index-headers.html0001104659-26-052956
Document: 0001104659-26-052956-index.html0001104659-26-052956
Document: 0001104659-26-052956.txt0001104659-26-052956
4 reports for PAHC
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PAHC — sortable, filterable
Type Now
May 6, 2026
5w ago
8-K
BULLISH ★ 6/10
$43.16 $31.79▼ −26.34%▼ −29.48%$31.53 (−26.95%)
May 5, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$58.50 $31.79▼ −45.66%▼ −48.44%$31.53 (−46.10%)
Apr 30, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$54.66 $29.74▼ −45.58%▼ −50.85%$31.53 (−42.32%)
Apr 27, 2026
6w ago
8-K
BEARISH ★ 5/10
$54.29 $33.68▲ +37.96%▲ +43.43%$31.53 (+41.92%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (49h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access